Piper Sees Blockbuster Revenue For Moderna Vaccine As Soon As Next Year
May 07, 2020 at 14:50 PM EDT
The analyst reiterates an Overweight rating on Moderna shares with a $57 price target after the FDA cleared the Phase 2 study to proceed.